News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving -1.18% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.05% for the day. Elsewhere, the Dow gained 0.46%, while the tech-heavy Nasdaq …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Gildan Activewear Inc. (GIL) saw its stock rise by 0.82% to C$70.48 on Friday, outperforming the S&P/TSX Composite Index which gained 0.50%. Despite this gain, the company's shares closed 29.8% below its 52-week high of C$100.44 reached in February.
Sharemaestro market context Price below Trend Line 52 weeks +3.5% · Next-week setup positive 56.7%BofA Securities has reiterated its Hold rating for Ermenegildo Zegna NV (ZGN.US) while simultaneously increasing its price target for the stock to $14.4. This adjustment reflects the firm's ongoing assessment of the luxury fashion company's market position and future prospects.
This article provides an "Enterprise value to revenue forward" metric for Gildan Activewear Inc. (MUN:VGA), listed on the Munich Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The content also lists various financial and community …
The European Medicines Agency's expert panel endorsed 12 new medicines and eight label expansions this week, impacting major pharmaceutical companies. Johnson & Johnson and Gilead are among the U.S. drugmakers receiving positive recommendations for their products. These approvals could allow J&J to enter the …
M.D. Sass LLC has reportedly taken a new position in Gildan Activewear, Inc. (NYSE:GIL), acquiring 396,504 shares valued at approximately $22.1 million, which now represents 1.7% of M.D. Sass's portfolio. This investment comes amidst positive Wall Street sentiment, with 13 Buy ratings and 4 …
Gilead Sciences announced that the European Medicines Agency's CHMP has recommended marketing authorization for Trodelvy in combination with Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. This recommendation is based on the ASCENT-04/KEYNOTE-D19 study, which showed a 35% reduced risk of disease …
– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19 Demonstrated a Highly Statistically Significant and Clinically Meaningful Reduction in the Risk of Disease Progression or Death – FOSTER CITY, Calif., …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Walleye Capital LLC has acquired a new position in Gildan Activewear, purchasing 24,934 shares valued at approximately $1.39 million during the first quarter. Institutional investors collectively own 82.83% of Gildan's stock, with several firms increasing their stakes, including Icon Advisers, Levin Capital Strategies, PNC …
The Swiss National Bank significantly increased its stake in Gildan Activewear (NYSE:GIL) by 27% in Q1, now holding 592,125 shares valued at $32.9 million. Analysts maintain a generally bullish outlook on GIL, with 13 Buy ratings, 4 Hold ratings, and a consensus price target …
This article announces that Ermenegildo Zegna N.V. has published a slide deck in conjunction with its H1 2026 Sales/Trading Statement Call. The content was provided by SA Transcripts, Seeking Alpha's team responsible for earnings call transcripts.
Key Points Interested in Ermenegildo Zegna N.V.? Here are five stocks we like better. Ermenegildo Zegna reported second-quarter 2026 revenue of EUR 517 million, up 11% organically, with management saying the quarter showed sequential acceleration and broad-based strength in direct-to-consumer sales. The company's retail-first …
The Law Offices of Frank R. Cruz are continuing their investigation into Gildan Activewear Inc. (GIL) on behalf of investors who lost money due to potential violations of federal securities laws. This investigation follows a report alleging that Gildan has been artificially inflating revenue …
Sharemaestro market context Price below Trend Line 52 weeks +3.5% · Next-week setup positive 56.7%The Law Offices of Frank R. Cruz is investigating Gildan Activewear Inc. for potential securities law violations after a report on June 16, 2026, accused the company of inflating revenues through channel stuffing and off-balance sheet receivables. This report caused an 18.8% drop in …
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention. The company's HIV business continues to maintain momentum, driven by solid performances of Biktarvy and Descovy, and incremental contributions from Yeztugo. Biktarvy …
Ermenegildo Zegna Group reported significant revenue growth in Q2 2026, with total revenues increasing 10.3% year-on-year to €517.1 million, and 11.0% on an organic basis, driven by strong performance across all brands. Direct-to-Consumer (DTC) sales were particularly strong, rising 16.4% to €410.9 million, reflecting …
Doctors Without Borders (MSF) urged Gilead Sciences and governments to make the HIV prevention medicine lenacapavir more accessible in low- and middle-income countries, especially Brazil. Lenacapavir is an injectable pre-exposure prophylaxis (PrEP) that is nearly 100-percent effective against HIV but is currently priced out …
Ermenegildo Zegna's shares remained flat in pre-market trading despite beating H1 revenue estimates, as a significant fall in Thom Browne wholesale revenues impacted overall performance. The luxury group reported H1 2026 revenues of €987.3 million, exceeding consensus, with strong growth in direct-to-consumer sales for …
Ermenegildo Zegna Group reported a 10.3% year-on-year increase in Q2 2026 revenues to €517.1 million, with organic growth reaching 11.0%. This growth was primarily driven by the strength of its Direct-to-Consumer (DTC) channel, which saw an organic increase of 17.3%, and strong performance in …
Icon Advisers Inc. Co. significantly increased its stake in Gildan Activewear, Inc. (NYSE:GIL) during the first quarter, purchasing 19,260 additional shares to bring its total holdings to 78,410 shares valued at approximately $4.36 million. This increase makes Gildan Activewear the 27th largest holding for …
Q2 2026 Group revenues increased +10.3% year‑on‑year (YoY) to €517.1 million and +11.0% on an organic basis, reflecting sequential acceleration across all brands, with ZEGNA leading the Group's performance. By Brand: ZEGNA brand revenues rose to €324.3 million up +16.9% YoY and +16.5% organic. …
Walleye Capital LLC significantly increased its stake in Ermenegildo Zegna N.V. (NYSE:ZGN) by 1,938.7% in the first quarter, now holding 665,851 shares valued at approximately $6.94 million. Other institutional investors also adjusted their positions, with 12.91% of the stock owned by institutions and hedge …
Zegna Group reported an 11% organic revenue growth in Q2 2026, reaching EUR 517 million, driven by strong demand in the Americas and Greater China, and sustained by a direct-to-consumer strategy. The ZEGNA brand was a key growth driver with 70% organic revenue increase, …
Gildan Activewear (GIL) is set to release its Q2 2026 earnings before market open on Thursday, July 30th, with analysts projecting $1.11 EPS on $1.61 billion in revenue. The company previously exceeded expectations in Q1 2026, reporting $0.43 EPS against a $0.36 consensus and …
Gilead Sciences is engaging cultural influencers and artists to combat HIV stigma and increase awareness, as scientific advancements in treating and preventing HIV are not being matched by public understanding. Despite progress turning HIV into a manageable chronic condition, knowledge about the virus is …
Girard Sharp LLP is investigating potential securities claims on behalf of former HanesBrands investors who received Gildan Activewear shares due to Gildan's acquisition of HanesBrands in December 2025. The investigation follows a decline in Gildan's stock price since the merger. Investors who experienced losses …
Bleichmar Fonti & Auld LLP is investigating Gildan Activewear Inc. (NYSE:GIL) for potential securities fraud following a significant stock drop on June 16, 2026. The investigation centers on allegations that Gildan engaged in a "channel stuffing" scheme to artificially inflate revenue. Investors who suffered …
Sharemaestro market context Price below Trend Line 52 weeks +3.5% · Next-week setup positive 56.7%Gilead Sciences (GILD) has seen a significant 126.8% return over the past five years, yet its stock remains undervalued according to various metrics and valuation models. Despite its strong performance, particularly in its HIV portfolio, and a P/E ratio close to the biotech industry …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Gilead Sciences and Merck will present detailed outcomes from their Phase 3 ISLEND-1 and ISLEND-2 trials at AIDS 2026. The investigational once-weekly oral HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) demonstrated effectiveness in virally suppressed adults with HIV who switched from …
The Rosen Law Firm has initiated an investigation into a potential class action lawsuit against Gildan Activewear Inc. The investigation follows allegations that Gildan issued misleading information about its organic growth and sales, leading to a significant stock price drop after a short seller …
Gilead Sciences announced its plans to release second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will host a webcast and conference call to discuss these results later that day. Interested parties can access the webcast and accompanying slides on the company's …
This article lists various ETFs that include Gilead Sciences, Inc. (GILD0) stocks in their portfolios. The ETFs are sorted by market value and provide details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year NAV total …
FOSTER CITY, Calif., July 21, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) have announced successful 48-week results for their once-weekly oral HIV regimen in two Phase 3 trials, ISLEND-1 and ISLEND-2. The trials showed that the treatment maintained viral suppression with a low percentage of patients above the viral-load threshold, …
Search by ticker symbol or company name and select a result to open its chart.